Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIV-Associated Neurocognitive Disorders

Surendra S. Ambegaokar and Dennis L. Kolson*

Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Abstract: Heme oxygenase-1 (HO-1) is a highly inducible and ubiquitous cellular enzyme that subserves cytoprotective responses to toxic insults, including inflammation and oxidative stress. In neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis, HO-1 expression is increased, presumably reflecting an endogenous neuroprotective response against ongoing cellular injury. In contrast, we have found that in human immunodeficiency virus (HIV) infection of the brain, which is also associated with inflammation, oxidative stress and neurodegeneration, HO-1 expression is decreased, likely reflecting a unique role for HO-1 deficiency in neurodegeneration pathways activated by HIV infection. We have also shown that HO-1 expression is significantly suppressed by HIV replication in cultured macrophages which represent the primary cellular reservoir for HIV in the brain. HO-1 deficiency is associated with release of neurotoxic levels of glutamate from both HIV-infected and immune-activated macrophages; this glutamate-mediated neurotoxicity is suppressed by pharmacological induction of HO-1 expression in the macrophages. Thus, HO-1 induction could be a therapeutic strategy for neuroprotection against HIV infection and other neuroinflammatory brain diseases. Here, we review various stimuli and signaling pathways regulating HO-1 expression in macrophages, which could promote neuronal survival through HO-1 modulation of endogenous antioxidant and immune modulatory pathways, thus limiting the oxidative stress that can promote HIV disease progression in the CNS. The use of pharmacological inducers of endogenous HO-1 expression as potential adjunctive neuroprotective therapeutics in HIV infection is also discussed.

Keywords: Dimethyl fumarate, heme oxygenase, HIV associated neurocognitive disorders, HO-1, oxidative stress, neuroinflammation.

Oxidative Stress in HIV Infection

Evidence for a role of oxidative stress in the pathogenesis of HIV infection in both systemic and central nervous system (CNS) compartments has consistently been demonstrated in HIV infected individuals. HIV infection can induce systemic oxidative stress [1-4] through both chronic immune activation [5-7] and direct effects of HIV proteins [8-10]. Individuals infected with HIV express diminished levels of glutathione – a potent endogenous antioxidant – in plasma and peripheral blood mononuclear cells (PBMCs) generally, and specifically in lymphocytes and monocytes [11-13]. Infected individuals also express elevated serum levels of the lipid peroxidation products malondialdehyde and hydroperoxide [14-16]. HIV infected cells demonstrate reduced levels of thioredoxin (a thiol antioxidant) [17], and the HIV proteins gp120 [8, 18-22], Vpr [10, 23], and Tat [9, 18] can directly induce cellular oxidative stress. Oxidative stress within infected cells can promote HIV replication through nuclear factor-kappa B (NF-kB)-driven transcriptional regulation [24-26] and inflammatory cytokine release [24, 27-31], thereby perpetuating systemic immune activation and disease progression. In clinical studies, markers for increased oxidative stress in plasma and circulating CD4+ T-lymphocytes correlate with disease progression in HIV infected individuals [32-34].

HIV infection of the brain, which likely occurs through infiltration of infected immune cells such as monocytes and T lymphocytes, also induces oxidative stress within the CNS [5, 6, 27, 35-37]. HIV proteins such as gp120 [8, 18, 38], Vpr [10, 39], and Tat [9, 18, 30] have been implicated in the direct induction of oxidative stress in several CNS cell types. In macrophages, the primary CNS reservoir for HIV replication, oxidative stress drives neurotoxin production [28, 37, 40-44], and markers of oxidative stress correlate with neurocognitive impairment [27, 43, 45] in HIV-infected individuals. Thus, the mechanisms and pathways by which HIV infection drives immune activation and its associated oxidative stress could be the targets for attenuating disease progression in both systemic and CNS compartments.

Although HIV does not infect neurons, HIV infection can result in a clinical syndrome of neurological and behavioral deficits known as HIV-associated neurocognitive disorders (HAND), which are pathologically associated with neuronal injury and neuronal loss. Chronic HIV infection in the CNS drives immune activation of resident macrophages and microglia, pervasive reactive astrocytosis, perivascular inflammation and infiltration of monocytic cells [46], which can result in HIV-encephalitis (HIVE), especially in those not receiving combination antiretroviral therapy (cART) [47]. Although the morbidity and mortality of HIV infection and the severity of neurocognitive impairment and associated neuroinflammation in HAND have significantly decreased

*Address correspondence to this author at the Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 280 Clinical Research Building, 415 Curie Blvd., Philadelphia, PA 19104, USA; Tel: 215-573-3505; Fax: 215-573-2029; E-mail: kolsond@mail.med.upenn.edu

1873-4251/14 $58.00+ .00 © 2014 Bentham Science Publishers
since the introduction of cART in 1996 [48-53], neuroinflammation persists at or above that observed in the pre-ART era [48, 50, 51, 53, 54], and systemic and CNS markers of activation of macrophages correlate with neurocognitive impairment in chronic HIV infection [55-63], even when HIV levels are controlled with cART [64-68]. Interestingly, the clinical severity of HAND correlates more with monocyte infiltration and monocyte-derived macrophages (MDM) and microglia activation than with CNS viral antigen load or number of HIV-infected cells in the brain [68-72].

MACROPHAGES AND MICROGLIA AS MEDIATORS OF HAND NEUROPATHOGENESIS

While systemic effects of HIV infection are likely driven by HIV infection of CD4+ T-lymphocytes, the CNS effects of infection are predominantly driven by HIV infection of macrophages and microglia. Within the CNS productive HIV infection, i.e. infection resulting in the production and release of new infectious virions, occurs in perivascular macrophages and microglia, while HIV infection in astrocytes is non-productive [73-76]. Monocytes originate from the bone marrow, travel through the vasculature, and can differentiate into dendritic cells (DCs) in the periphery, or given the appropriate chemotaxis signal can transverse across the endothelial cell barrier into underlying end-organs; DCs do not cross this vascular barrier as readily as monocytes. After or during transmigration, monocytes differentiate into perivascular macrophages, often referred to as monocyte-derived macrophages (MDM). Monocytes express the receptor CD14, and all cells of the monocyte-lineage – e.g. MDM and DC – continue to express CD14 after differentiation. Migration of HIV-infected monocytes across the blood-brain-barrier (BBB) is believed to be the primary source of HIV entry into the CNS. However, it should be noted that other possible routes of HIV entry into the brain include transmigration of HIV-infected T lymphocytes from the blood into CNS tissue or parenchyma [77-79], and infection of or transcytosis through brain microvascular endothelial cells that comprise the BBB [80-86], although there is limited pathological evidence for these routes of entry. See Fig. (1) for a schematic model of HIV neuropathogenesis.

It is still uncertain how and when HIV enters the CNS, and two different models have been proposed: the “Trojan horse” and “late invasion” models. In the “Trojan horse” model, the virus is carried across the BBB early during the course of infection by infiltrating macrophages, and only later during infection, the virus is activated to replicate, recruiting additional monocyte/macrophages into the CNS via cytokine and chemokine signaling, and increased BBB permeability. In the “late invasion” model, chronic immune dysregulation in the periphery leads to an expansion of activated monocyte population from bone marrow that is highly invasive into the CNS and other end-organs [87].

MACROPHAGE NEUROTOXIN PRODUCTION

The neuropathology of HAND is described as decreased CNS neuronal synaptic and dendritic density [70, 88, 89], neuronal cell death [72, 90-92], and altered neuronal cell function [93-101], each of which has been linked to persistent inflammation and oxidative stress. These neurotoxic effects likely result from effects of soluble factors released from HIV-infected monocyte-derived macrophages (HIV-MDM) and immune-activated MDM, microglia and astrocytes [102-105]. Many studies have implicated excitotoxic activity through N-methyl-D-aspartate-receptor (NMDAR) over-activation [106-108]. The other neurotoxins released from HIV-MDM or microglia are glutamate [109], quinolinic acid [110, 111], NTox [112], platelet activating factor [113], TNFα [114], and the HIV proteins gp120 [115, 116] and Tat [108, 117] and others. Analysis of cerebrospinal fluid (CSF) from HIV-infected individuals demonstrated increased levels of glutamate [118-120], quinolinic acid [111, 112], platelet activation factor [113], TNFα [108, 114], and other excitotoxins, which correlate with increased severity of HAND and with neuroinflammation. Several of these neurotoxins also alter astrocyte function, in particular glutamate homeostasis.

HEME OXYGENASE-1 AND HIV CNS INFECTION

Despite the multi-faceted nature of CNS damage by HIV, there may be an innate host response to combat the pathological effects of neuroinflammation and oxidative stress. Heme oxygenase-1 (HO-1, alternatively referred to as heat shock protein-32, HSP32), initially identified as a phase II detoxifying enzyme that degrades free heme, has been shown to have potent anti-oxidant qualities and to be highly inducible in response to numerous toxic insults, including heat-shock [122-127], ultraviolet radiation [128], ischemia and/or hypoxia [129-131] or hyperoxia [132], heavy metals [130, 133, 134] and exposure to reactive oxygen species (ROS) [126, 128, 135-141]. To counter the neuroinflammation and oxidative stress, a normal cellular response is acute induction of HO-1 expression, which generates the potent antioxidants bilirubin and biliverdin, as well as carbon monoxide, which has also pro-survival effects [142, 143]. However, whether this response occurs within the CNS during HIV infection has not been reported.

HO-1 is highly expressed in CNS cells, primarily astrocytes, macrophages and microglia, particularly during brain injury in several disease states, including Alzheimer’s disease [144-146], Parkinson’s disease [147-149], Pick disease [150], Huntington’s disease [151] and multiple sclerosis [152, 153] (for more reviews on neurodegenerative disorders: [154-157]). Recent work from our lab has demonstrated a deficiency of HO-1 expression in the brains of individuals with HAND with and without encephalitis (Gill et al. in revision), and in HIV-MDM in vitro [158], which suggests a possible role for HO-1 deficiency in the neuropathogenesis of HAND.

HEME, HEMOGLOBIN SCAVENGING AND HHEME OXYGENASE-1 INDUCTION

As the name suggests, a primary function of heme oxygenase is to metabolize heme. Heme is a porphyrin molecule with a bound iron (Fe2+) ion, and is a prosthetic group used by hemoglobin and myoglobin proteins to
transport oxygen \( (O_2) \) by the binding of \( O_2 \) to \( Fe^{++} \). Erythrocytes also known as red blood cells (RBCs) are abundant with heme due to their abundance in hemoglobin, as the primary carriers of oxygen to tissues not capable of direct gas exchange with the external environment. Macrophage scavenging and phagocytosis of hemoglobin-containing senescent erythrocytes (but not erythrocytes without hemoglobin) induce HO-1 expression [136, 159]. Indeed, monocytes/macrophages appear to function as the major scavenger of free hemoglobin in the vasculature. Monocytes/macrophages express the membrane protein CD163, which binds to free hemoglobin [160-162] and induces HO-1 expression [163-165]. HO-1 expression is essential for monocytes/macrophages viability during erythrophagocytosis as such cells deficient in HO-1 (HO-1 \(-/-\)) die due to this activity [166].

Free heme or hemin also induces HO-1 in monocytes/macrophages [167-169]. Macrophages also express CD91/lipoprotein receptor related protein (LRP), which scavenges free hemoglobin and induces HO-1 transcription upon binding [170]. Interestingly, CD91/LRP is expressed in several other cell types, such as neurons,

Fig. (1). Model of HIV Neuropathogenesis. HIV infected immune cells, including CD4+ T cells and CD14+ monocytes, circulate through the blood and produce reactive oxygen species (ROS), which can further enhance viral replication and release. Infected or activated immune cells can also release the pro-inflammatory cytokines, TNF-\( \alpha \) and IL-1\( \beta \), which ROS can exacerbate. HIV proteins – gp120, Tat, and Vpr – may also be released and induce toxicity independently of infectious virions. ROS contribute to increased blood brain barrier (BBB) permeability, which can allow for increased entry of infected immune cells (e.g. monocytes) from the blood into central nervous tissue; infected T lymphocytes may also be a source of virus entry into the CNS. As monocytes enter the nervous tissue they differentiate into macrophages, and release IFN-\( \gamma \) in addition to TNF-\( \alpha \). HIV may replicate in macrophages and may be transmitted to microglia, which in turn can further replicate and transmit HIV. Infected or immune-activated microglia or macrophages can produce IFN-\( \gamma \) and TNF-\( \alpha \) in a positive feedback loop, and can release a host of neurotoxic factors. Most neurotoxicity is initially limited to synaptic loss and decrease in dendritic density that is dependent on the NMDA-type glutamate receptor. This leads to eventual loss of neuronal function and finally neuronal death. HIV can infect but not productively replicate in astrocytes. Activated astrocytes have abnormal glutamate metabolism, leading to excess glutamate release and excitotoxicity. TNF-\( \alpha \) and IL-1\( \beta \) stimulation of astrocytes can further increase glutamate release. Astrocytes, microglia and macrophages are potent inducers of heme oxygenase-1 (HO-1), which is downregulated in infected macrophages and in HIV-infected brains, and thus may also contribute to neuropathogenesis of HIV infection; neurons demonstrate very limited expression of HO-1. Red arrows indicate potential neurotoxins or direct neurotoxic pathways.
although it is unclear if it also functions to scavenge hemoglobin or induce HO-1 in neurons [170]. This induction of HO-1 in monocytes/macrophages through hemoglobin/heme binding, however, can be abrogated by other cellular cues. In particular, binding of the platelet derived CXCL4 inhibits CD163 expression and thus also HO-1 induction [171]. Exposure to lipopolysaccharide (LPS) can also inhibit CD163 expression and HO-1 induction in monocytes [162]. Moreover, oxidized hemoglobin induces a structural alteration that does not allow binding of CD163 to signal downstream to increase HO-1 expression [172]. Thus HIV may indirectly reduce HO-1 in monocytes/macrophages due to the increased levels of ROS and oxidative damage in HIV infection.

HO-1 enzymatic breakdown of heme yields bilirubin, which is further converted to biliverdin, both of which are potent free radical scavengers. Thus, macrophages can induce HO-1 to counteract the high levels of ROS they produce during phagocytosis, including phagocytosis of parasites, which are released in order to better destroy the engulfed material [173-175]. Indeed, exposure to external ROS can induce HO-1 in monocytes/macrophages [139, 176, 177]. HO-1 may also induce the production of glutathione, another potent endogenous antioxidant [173, 178], and depletion of glutathione may itself trigger HO-1 induction [179].

INFECTIONOUS AGENTS AND HEME OXYGENASE-1: BENEFICIAL AND INJURIOUS RESPONSES

In addition to heme metabolism and oxidative stress, monocytes/macrophages increase HO-1 expression in response to viral and bacterial agents as well. Several studies have shown robust induction of HO-1 in monocytes/macrophages following exposure to LPS, typically found in Gram-negative bacteria [180-185]. Also, in at least one study, HO-1 is found to be induced by and protective against non-tuberculous mycobacterial infection [186]. HO-1 is also induced during tuberculosis infection, however it is unclear whether this promotes or reduces infection [187]. Herpes simplex virus-1 (HSV-1) encephalitis induces a strong HO-1 response in macrophages in the brain [188, 189]; and infection of neurotropic Borna disease virus (BSV) in the brain leads to sustained HO-1 induction in activated microglia, reactive astrocytes and mononuclear infiltrates for up to 4 weeks post-infection, presumably as a neuroprotective response [190].

The macrophage production of HO-1 during other parasitic infections might subserve both beneficial and injurious responses. As monocytes/macrophages express HO-1 to protect against the ROS they release to kill engulfed pathogens, induction of HO-1 helps to promote monocytes/macrophages survival and maintain degradative function. However, certain parasites have found ways to exploit the protective effects of HO-1 expression in monocytes/macrophages. For example, *Leishmania chagasi* promastigote infection in macrophages, persists longer in macrophages that express HO-1 [191], and the ability of HO-1 to reduce superoxide production is thought to aid in *Leishmania Mexicana pifano* amastigote infection [174]. However, drugs that are successful in controlling *Leishmania donovani* appear to do so by increasing HO-1 expression in THP-1 mononuclear lines [192].

In contrast, higher HO-1 expression is associated with increased susceptibility to malaria (*Plasmodium falciparum*) infection [193-196]. This may be due to the heme overload from malaria-induced hemolysis, from which increased HO-1 activity would lead to an overload of free iron [197]. HO-1 expression is high in the malaria-infected brain, monocyte cells and microglia that surround the classic malaria granulomas (Dürck’s granulomas), [198]; however, whether this is a beneficial or injurious response to bleeding and free hemoglobin rather than a direct response to the malaria pathogen is unknown, as other reports have found that HO-1 expression can be protective against the disease [199, 200].

INJURY-INDUCED HEME OXYGENASE-1 EXPRESSION IN THE BRAIN

Although neurons appear to have little to no HO-1 inducibility within the brain, some neurons in the spinal cord peripheral nervous system (PNS) show increased HO-1 expression in response to injury [201-203]. Some reports indicate that cortical neurons can express HO-1, if only for a few hours [204-207]. In contrast, HO-1 is robustly expressed in astrocytes, macrophages, microglia, and oligodendrocytes in response to injury [201, 208, 209], including hypoxia/ischemia [204, 207, 210].

Perivascular macrophages within the brain can express high levels of immunoreactive HO-1 during injury. This is especially true where there is hemorrhage [201, 205, 211, 212]. In particular, CD163+ macrophages appear to be primary inducers of HO-1, at least in response to traumatic brain injury (TBI) [213, 214]. Increased permeability of the BBB is also sufficient to induce HO-1 expression in astrocytes and macrophages/microglia [215]. There is prolonged expression of HO-1 in microglia and macrophages, with reports of up to 42 days [203], 5 months [206], or 6 months after the initial injury [216].

FUNCTIONAL CONSEQUENCES OF INDUCED BRAIN HO-1 EXPRESSION

In most reports, the increased expression of HO-1 is thought to be neuroprotective given the many beneficial cellular effects of HO-1 [157]. However, there is evidence that in some cases HO-1 induction may exacerbate injury, and therapeutic interventions that reduce HO-1 in glia have been proposed for certain neurodegenerative diseases [156]. For example, Wang & Doré [212] reported that HO-1 knock-out mice had less brain injury due to intracerebral hemorrhage than their wild-type counterparts, along with overall reduction in leukocyte infiltration, microglial/macrophage activation, and free radical levels. Also, macrophage cell lines (RAW 264.7) that express the Apo-ε4 allele — a known genetic risk factor for Alzheimer’s disease — express higher levels of HO-1 than cells expressing the Apo-ε3 allele [217].

There are some interesting reports of brain injury surprisingly causing damage in other organ systems. For example, increased macrophage HO-1 expression in either the kidney or lung is seen in brain death during kidney
transplantation [218], and acute lung injury following TBI [219]. This suggests that either there is a humoral signal released within the brain (e.g. monocytes/macrophages, astrocytes, microglia, neurons) that activates macrophages in the periphery, or that macrophages activated in the injured brain are able to migrate out of the CNS into the periphery and into other organs. These findings may suggest that constitutive HO-1 expression in non-injured or healthy tissue may cause tissue damage, and may be the reason HO-1 is expressed as an inducible rather than a constitutive protein.

There are numerous examples of beneficial effects of HO-1 induction in the CNS. Induction of HO-1 in astrocytes is reported to reduce microglial activation, ROS levels and leukocyte infiltration in a mouse model of HSV-1 encephalitis [189], and HO-1 is briefly induced in astrocytes following excitotoxicity [220]. In addition, some metabolites of the kynurenine pathway expressed in activated macrophages and microglia - hydroxyanthranilic acid (3-HAA) and 3-hydroxykynurenine (3-HK) – inhibit cytokine release and cytokine-induced neuronal death, which may be due to the ability of 3-HAA to induce HO-1 in astrocytes [221]. HO-1 expression in macrophages/microglia is particularly beneficial in the spinal cord, as shown in experimental autoimmune encephalitis mouse models [222] and spinal cord injury [223]. Furthermore, HO-2 may be neuroprotective, as neuronal expression of HO-2 is increased in response to hypoxia-ischemia [207], and HO-2 knock-out mice show increased brain swelling, neuronal death, leukocyte infiltration, free radicals and activation of astrocytes and microglia/macrophages due to intracerebral hemorrhage in comparison with wild-type mice with intracerebral hemorrhage [224].

**SIGNALLING PATHWAYS OF HEME OXYGENASE-1 EXPRESSION**

The canonical mechanism of HO-1 induction is related to the antioxidant response (AR) pathway mediated by the master transcriptional regulator, nuclear factor erythroid-2 related factor 2 (Nrf2). Nrf2 is normally sequestered in the cytosol by its binding partner, Keap1, which helps target Nrf2 for degradation [225]. However, upon exposure to oxidative stress, Keap1 is degraded, which allows Nrf2 to translocate to the nucleus and activate transcription of many genes that function to protect and repair damage due to oxidative stress [226]. However, the specific signaling pathway(s) of Nrf2 activation are still unclear, as several regulatory kinases have been implicated, which may vary due to the type of stimulus the cell detects.

There appear to be several signaling pathways that can lead to HO-1 expression. LPS is commonly used to induce HO-1 expression; and as the major detector of LPS, Toll-like receptor-4 (TLR4) would be predicted to mediate HO-1 induction. Indeed, several studies have shown TLR4-mediated HO-1 induction, particularly in macrophages [182, 184, 227] and MyD88-dependent signaling of HO-1 expression [228]. There appears to be a negative feedback loop whereby HO-1 induction leads to decreased TLR4 expression [229, 230], or inhibits the signaling properties of TLR4 [231, 232]. The alpha7 nicotinic acetylcholine receptor [233] and the beta adrenergic receptor in RAW 264.7 macrophage cell lines [234] are also reported to initiate HO-1 expression, either through protein kinase C (PKC) or protein kinase A (PKA), respectively. Some reports state the HO-1 expression is signaled via PKC activity [183, 235], while others report extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK)-mediated induction [236, 237], and perhaps activation of both PKC and ERK [238]. ERK may also regulate HO-1 production at the translational level rather than at the transcriptional level [239]. Other major kinases have also been shown to function in HO-1 induction, including p38 MAPK [231, 240-246] and c-Jun N-terminal kinase (JNK) 1/2 [247, 248].

While many reports show or suggest Nrf2-dependent binding to the antioxidant response element (ARE) in the HO-1 promoter as the major inducer of HO-1 expression [249], there is evidence for Nrf2 independent HO-1 induction. The transcription factor activator protein-1 (AP-1) binds to at least 2 different enhancer elements (4kb and 6kb upstream) in the HO-1 promoter, and such binding is necessary for LPS and hyperoxia-mediated induction of HO-1 [180, 250, 251]. In ethanol induction of HO-1, Nrf2 was explicitly determined to be nonfunctional in HO-1 expression while AP-1 was necessary [248]. The HO-1 promoter also contains a cAMP-response element (CRE) approximately 650 bp upstream of the transcription start site, which is necessary for HO-1 induction [252]. AP-1 can bind this region, as well as the transcription factor CREB (cAMP-response element binding) protein, known to be regulated by PKA [253, 254]. The HO-1 promoter also contains binding sites for nuclear factor-kappa B (NF-κB) 156 bp and 370 bp upstream from the transcription start site [181, 255-257]. It is also reported that HO-1 leads to reduced NF-κB p65/Rel A levels [258, 259], which may suggest a negative feedback mechanism of NF-κB.

**CYTOKINE AND HEME OXYGENASE-1 SIGNALING AND FEEDBACK**

Apart from the primary enzymatic function of heme catabolism, and bilirubin and carbon monoxide production, all of which have cytoprotective effects, increased HO-1 expression also correlates with altered expression of several cytokines. In many reports, HO-1 appears to promote the expression of anti-inflammatory cytokines and dampen the expression of pro-inflammatory cytokines. Interleukin-10 (IL-10) is a classic anti-inflammatory cytokine, and several reports have shown that induction of HO-1 directly leads to increased IL-10 production [260-265]. Furthermore, HO-1 expression inhibits expression of the prototypical pro-inflammatory cytokine tumor necrosis factor-alpha (TNFα) [230, 263, 264, 266, 267]. Induction of HO-1 also reduces expression of other pro-inflammatory cytokines such as IL-1β [267, 268], IL-6 [175, 261, 269], IL-33 [230] and monocyte chemoattractant protein-1 (MCP-1) [175, 259, 267, 270, 271].

At the same time, these HO-1 regulated cytokines may feedback to regulate HO-1 expression itself. In macrophages, IL-6 appears to increase HO-1 [272], while TNFα treatment in CD14+ cells leads to decreased HO-1 expression [273]. Several reports show that exposure to IL-10 directly induces HO-1 [163, 272, 274-276]. Furthermore, some evidence suggests that IL-10-induced inhibition of TNFα expression
is mediated by HO-1 expression [241]. In microglia, IL-10 and HO-1 appear to be co-induced by the anti-inflammatory cytokine, IL-34 [277], further implicating a synergistic association between IL-10 and HO-1.

Although most reports point to the anti-inflammatory properties of HO-1, there are a few studies to the contrary. In RAW 264.7 macrophages, HO-1 inhibition is associated with decreased TNFα expression [268]; however the reverse experiment of HO-1 induction has not been performed to confirm this conclusion. It is also reported that HO-1 induces MCP-1 expression, although contradictory evidence has been published. In one study, genetic deficiency of HO-1 in macrophages (and other myeloid cells) resulted in reduced MCP-1 expression upon viral infection or TLR3 and TLR4 stimulation [222]; however given the range of other cytokines and downstream transcription processes HO-1 regulates, it is difficult to state a direct effect of HO-1 expression leading to increased MCP-1 production. Another study with epithelial cells also reported increased MCP-1 with increased HO-1, using hemin as an inducer of HO-1 [278]; while hemin is a strong inducer of HO-1, it may also trigger other signaling pathways that regulate MCP-1 expression independently of HO-1. Indeed, the authors state that there is a delayed phase of MCP-1 in these conditions that is HO-1 independent, which may suggest that hemin co-induces HO-1 with MCP-1 to function as a negative regulator of MCP-1. HO-1 also decreases interferon-beta (IFN-β) [222] and interferon-gamma expression (IFN-γ) [266], which may serve either pro- or anti-inflammatory functions depending on the cell-type and surrounding cytokine milieu. Fig. (2) illustrates some of the signaling interactions described here.

THERAPEUTIC POTENTIAL OF EXOGENOUS INDUCERS OF HEME OXYGENASE-1 EXPRESSION

Since HO-1 initiates potent endogenous antioxidant responses, induction of HO-1 expression has therapeutic potential for several diseases in which oxidative stress is symptomatic, including HIV infection. Treatment of mice with cobalt IX protoporphyrin (CoPP), a powerful HO-1 inducer, was shown to promote graft survival in a model of kidney transplantation [266]. However, HO-1 inducers used in vitro, including LPS, hemin, or protoporphyrins, have limited clinical relevance given the range of negative side effects and/or limited tolerability or bioavailability. Gene-therapy models have also been developed to more permanently induce HO-1 in target cell types [260, 279]. While promising, this type of approach may be beneficial only in certain conditions, and such therapies have not yet been fully validated in the clinical setting. A more immediate and simpler approach is the use of orally available compounds that can induce HO-1 in vivo.

Many studies have shown that a number of plant-based extracts (phytopharmaceuticals) induce HO-1, leading to ameliorated oxidative stress and inflammation. The sources of these compounds are several different plant species and plant organs, ranging from seeds to fruits to leaves to roots [238, 245, 247, 280-293]. Some of these compounds can be found in commonly-used plants, such as brown rice [294], Chinese cinnamon [295] or Ginkgo biloba [243, 296]. Curcumin and omega-3 fatty acids are well-studied natural compounds with antioxidant and anti-inflammatory properties that might be related to their potent induction of HO-1 [270, 297-300], although it is not clear if their effects are directly due to their induction of HO-1. As dietary compounds that can be administered orally, such phytopharmaceuticals offer the promise of easily available therapy with potentially high tolerability. However, caution must be prioritized in directly translating these in vitro studies to the clinical setting, as no rigorous clinical trials have been performed for many of these compounds. The question of dosage, metabolism and bioavailability will need further and extensive study to determine the efficacy and safety of such compounds as a form of treatment.

Currently, there are two classes of FDA-approved drugs that have the immediate potential for testing HO-1 induction in clinical trials: statins and fumaric acid esters (FAEs). Statins have been widely prescribed to reduce cholesterol
levels by inhibiting HMG-CoA reductase [301]. However, in vitro and in vivo rodent models have shown that statins can robustly induce HO-1 in monocytes/macrophages, leading to reduction of inflammation [302-305]. BBB-permeable statins therefore have the potential to induce HO-1 in cells of the CNS, including macrophages, microglia, and astrocytes, although such studies have yet to be reported.

Fumaric acid esters, on the other hand, have a demonstrated effect in the CNS. In particular, a formulation of dimethyl fumarate (DMF) trade-marked as Tecfidera, was approved by the FDA on March 27, 2013 for the treatment of multiple sclerosis (MS). DMF is orally delivered, and is quickly metabolized to monomethyl fumarate (MMF), and both compounds exert similar, though not equivalent, biological activities (for review see Gill & Kolson 2013 [306]). DMF functions as an immune modulator, and it was initially approved to treat psoriasis in Germany [307, 308]. Work from our lab has demonstrated that DMF/MMF can robustly induce HO-1 in macrophages [158], and others have shown the same effect in type II dendritic cells [309]. Furthermore, we have shown that DMF/MMF treatment of HIV-infected macrophages significantly attenuates the release of soluble neurotoxins. Pre-treatment of macrophages with DMF/MMF before HIV inoculation reduces HIV infection [158]. The reduction of neurotoxin release is clearly mediated by the increased HO-1 elicited by DMF/MMF, while the suppression of HIV infection might be related to inhibition of NFκB translocation [158]. The inhibition of HIV replication by HO-1 induction has also been previously observed in monocytes, using hemin as a stimulant [310], and in MDM using LPS to induce HO-1 [311]. The correlation with increased HO-1 and decreased HIV replication has been recently demonstrated in clinical studies in which HIV+ patients with lower HO-1 expression were found to have higher levels of viremia (when removed from cART) [312]. The effects of HO-1 induction in the CNS of HIV+ patients and its relation to HAND remain to be examined; however, given the proven CNS efficacy of DMF in suppressing inflammation and immune activity in MS patients, DMF stands as a compelling candidate for HAND and other HIV-associated disorders in other tissues (kidney, liver, heart, bone) not derived from opportunistic infections.

CONCLUSION

As this review highlights, there are several pathways through which HO-1 may be induced or activated, in monocytes/macrophages (the primary HIV reservoir in the CNS) and in CNS cells such as astrocytes and microglia, and even neurons in certain circumstances. Increased HO-1 expression in these cell types has the potential to reduce several salient features of HAND and other HIV associated end-organ diseases that have oxidative stress and chronic immune activation as common symptoms. Several classes of pharmaceuticals, from fumaric acid esters (e.g. DMF or MMF) to statins to phytochemicals, have the potential to target these pathways to be tested or developed for HIV adjunctive therapy in addition to current anti-retroviral therapy, and may also aid in the treatment for other neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease.

LIST OF ABBREVIATIONS

| Abbreviation | Full Form |
|--------------|-----------|
| AP-1         | Activator protein 1 |
| ARE          | Antioxidant response element |
| BBB          | Blood-brain barrier |
| cART         | Combined anti-retroviral therapy |
| CNS          | Central nervous system |
| DC           | Dendritic cell |
| DMF          | Dimethyl fumarate |
| HAND         | HIV-Associated Neurocognitive Disorders |
| HIV          | Human immunodeficiency virus |
| HIVE         | HIV Encephalitis |
| HIV-MDM      | HIV infected monocyte-derived macrophage |
| HO-1         | Heme oxygenase-1 |
| HSV-1        | Herpes simplex virus-1 |
| IFNβ         | Interferon-beta |
| IFNγ         | Interferon-gamma |
| IL-10        | Interleukin 10 |
| IL-1β        | Interleukin 1 beta |
| LPS          | Lipopolysaccharide |
| MCP          | Monocyte chemoattractant protein 1 |
| MDM          | Monocyte-derived macrophage |
| MMF          | Monomethyl fumarate |
| MS           | Multiple sclerosis |
| NF-κB        | Nuclear factor kappa B |
| Nrf2         | Nuclear factor erythocyte-2 related factor 2 |
| PBMC         | Peripheral blood mononuclear cells |
| PNS          | Peripheral nervous system |
| ROS          | Reactive oxygen species |
| TBI          | Traumatic brain injury |
| TLR          | Toll-like receptor |
| TNFα         | Tumor necrosis factor alpha |

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

We would like to thank A.J. Gill for his review of the manuscript and figure, and we thank the editors, including J. Rappaport, for their support of this submission. We acknowledge our funding sources, NIH-MH097671 and NIH-NS-07180.

PATIENT CONSENT

Declared none.
REFERENCES

[1] Perl A, Banki K. Genetic and metabolic control of the mitochondrial transmembrane potential and reactive oxygen intermediate production in HIV disease. Antioxidants and Redox Signaling 2000; 2(3): 551-73.

[2] Elbim C, Pillet S, Prevost MH, Preira A, Girard PM. The role of phagocytes in HIV-related oxidative stress. Journal of Clinical Virology 2001; 20(3): 99–109.

[3] Allard JP, Aghdassi E, Chau J, Salit I. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. American Journal of Clinical Nutrition 1998; 67(1): 143–7.

[4] Repetto M, Reides C, Carrerero MG, Costa M. Oxidative stress in blood of HIV infected patients. Clinica Chimica Acta 1996; 255(2): 107–17.

[5] Valveur V, Shiramizu B. HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion 2004; 4(2-3): 119-29.

[6] Mollace V, Nottet HS, Clayette P, et al. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends in Neurosciences 2001; 24(7): 411-6.

[7] Aukrust P, Svardal AM, Müller F, Lunden B, Berge RK, Froiland SS. Decreased levels of total and reduced glutathione in CD4+ lymphocytes in common variable immunodeficiency are associated with activation of the tumor necrosis factor system: possible immunopathogenic role of oxidative stress. Blood 1995; 86(4): 1383-91.

[8] Ronaldson PT, Bendayan R. HIV-1 viral envelope glycoprotein gp120 produces oxidative stress and regulates the expression of multidrug resistance protein-1 (Mrp1) in glial cells. Journal of Neurochemistry 2008; 106(3): 1298–313.

[9] Turcan-Cholewo J, Dimayuga FO, Gupta S, et al. Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. Journal of Neurochemistry 2009; 108(1): 202-15.

[10] Deshmule SL, Mukerjea R, Fan S, et al. Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1 alpha expression. Journal of Biological Chemistry 2009; 284(17): 11364-73.

[11] Eck HP, Gmünder H, Hartmann M, Petzoldt D, Daniel V, Dröge W. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biological Chemistry 1989; 370(2): 101-8.

[12] de Quay B, Malvinieri R, Lauherber BH. Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS 1992; 6(8): 815-9.

[13] Malvy DJ, Richard MJ, Arnaud J, Favier A, Amede-Manesme O. Relationship of plasma malondialdehyde, vitamin E and antioxidant micronutrients to human immunodeficiency virus-1 seropositivity. Clinica Chimica Acta 1994; 224(1-2): 87-94.

[14] Sonnerborg A, Carlin G, Akerlund B, Jarstrand C. Increased production of malondialdehyde in patients with HIV infection. Scandinavian Journal of Infectious Diseases 1988; 20(3): 287-90.

[15] Revillard JP, Vincent CM, Favier AE, Richard MJ, Zittoun M, Kazatchkine MD. Lipid peroxidation in human immunodeficiency virus infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 6(4): 223-9.

[16] Foga IO, Nath A, Hasinoff BB, Geiger JD. Antioxidants and dipyridamol inhibit HIV-1 gp120-induced free radical-based oxidative damage to human monocyteid cells. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 16(4): 223-9.

[17] Otis JS, Ashikmin YL, Brown LAS, Guidot DM. Effect of HIV-1-related protein expression on cardiac and skeletal muscles from transgenic rats. AIDS Research and Therapy 2008; 5: 8.

[18] Yu Q-R, Zhang Z-P, Zhang H, et al. Inducible nitric oxide synthase is involved in the oxidative stress induced by HIV-1 gp120 in human retina pigment epithelial cells. Chinese Medical Journal 2008; 121(24): 2578-83.

[19] Revillard JP, Vincent CM, Favier AE, Richard MJ, Zittoun M, Kazatchkine MD. Lipid peroxidation in human immunodeficiency virus infection. Antioxidants and Redox Signaling 2007; 9(12): 177-83.

[20] Störmajer-Rácz T, Gazdag Z, Belágyi J, Vágvölgyi C, Zhao RY, Pestl M. Oxidative stress induced by HIV-1 F34IVp1 in Schizosaccharomyces pombe is one of its multiple functions. Experimental and Molecular Pathology 2010; 88(1): 38-44.

[21] California. F. G. A. N. O. P. I. T. H. T. T. P. N. A. N. E. R. N. E. A. M. E. D. I. N. C. Clinical. Letters 2000; 112-113: 177-83.

[22] Israel N, Haughey NJ, Cutler RG, Tamara A, Delia D, Kurrle R, Colombo MP. Apoptosis induced by HIV-gp120 in a Th1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering. FEBS Letters 1997; 411(1): 87-92.

[23] Roc AC, Ances BM, Chawla S, et al. Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Archives of Neurology 2007; 64(9): 1249-57.

[24] Reddy PVB, Agudelo M, Atturi VSR, Nair MP. Inhibition of nuclear factor erythroid 2-related factor 2 exacerbates HIV-1 gp120-induced oxidative and inflammatory response: role in HIV-associated neurocognitive disorder. Neurochemical Research 2012; 37(8): 1697-706.

[25] Fuchs J, Oelke N, Imhof M, et al. Multiparameter analysis of clastogenic factors, pro-oxidant cytokines, and inflammatory markers in HIV-1-infected patients with asymptomatic disease, opportunistic infections, and malignancies. Molecular Medicine 1998; 4(5): 333-43.

[26] Wanchu A, Rana SV, Pallikkuth S, Sachdeva RK. Short communication: oxidative stress in HIV-infected individuals: a cross-sectional study. AIDS Research and Human Retroviruses 2009; 25(12): 1307-11.

[27] Ibeh BO, Emeka-Nwabunna IK. Increased oxidative stress condition found in different stages of HIV disease in patients undergoing antiretroviral therapy in Umuahia (Nigeria). Immunopharmacology and Immunotoxicology 2012; 34(6): 1060-6.

[28] Suresh DR, Annam V, Pratibha K, Prasad BV. Total antioxidant capacity and depleted total antioxidant capacity of serum samples. American Journal of Clinical Pathology 1998; 109(3): 268-73.

[29] McLemore JL, Beeley P, Thorton K, Morrisroe K, Blackwell W, Dasgupta A. Rapid automated determination of lipid hydroperoxide concentrations and total antioxidant status of serum samples from patients infected with HIV: elevated lipid hydroperoxide concentrations and depleted total antioxidant capacity of serum samples. American Journal of Clinical Pathology 1998; 109(3): 637-8.

[30] Price TO, Ercal N, Nakaoke R, Banks WA. HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Research 2005; 1045(1-2): 57-63.
neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience 2001; 107(1): 51-8.

Ferrucci A, Nonnemacher MR, Cohen EA, Wigdahl B. Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir. Virus Research 2012; 167(2): 358-69.

Shi B, Raina J, Lorenzo A, Buclechier C, Ritter M, Orsò E. Regulation of scavenger receptor CD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive testing in advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes 2012; 60(3): 234-43.

Velazquez I, Pfau M, Wojna V, Skolasky R, Laspurp J, Melendez LM. Antioxidant enzyme dysfunction in monocytes and CSF of Hispanic women with HIV-associated cognitive impairment. Journal of Neurommunology 2009; 206(1-2): 106-11.

Tian C, Sun L, Jia B, et al. Mitochondrial glutaminase release contributes to glutamate-mediated neurotoxicity during human immunodeficiency virus-1 infection. Journal of Neuroimmunology Pharmacology 2012; 7(3): 619-28.

Bell JE. An update on the neuropathology of HIV in the HAART era. Histochem Suppl. 1992; 42: 107-14.

Gelman BB. HIV-1 Neuropathology. The Neurology of AIDS. 2012; In: Gendelman HEG I, Everall IP, Fox HS, Gelbard HA, Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE.

Weaver LK, Pioli PA, Wardwell K, Vogel SN, Guery PM. Up-regulation of human monocyte CD163 upon activation of cell surface Toll-like receptors. Journal of Leukocyte Biology 2007; 81(3): 663-71.

Timmermann M, Högger P. Oxidative stress and 8-isoprostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of monocyte/macrophage necrosis factor-alpha from human monocytes. Free Radical Biology and Medicine 2005; 39(1): 98-107.

Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997-2010. Current Opinion in HIV and AIDS 2010; 5(6): 480-90.

Nixon DE, Lassam A. Biomarkers of immune dysfunction in HIV. Current Opinion in HIV and AIDS 2010; 5(6): 498–503.

Lyons J, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. Journal of Acquired Immune Deficiency Syndromes 2011; 57(5): 371-9.

Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. Journal of Infectious Diseases 2011; 204(1): 154-63.

Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with nondiabetic coronary plaque in HIV-infected patients. Journal of Infectious Diseases 2011; 204(8): 1227-36.

Burdo TH, Weifenbach A, Woods SP, Letendre S. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS. 2013;27(9):1387–95.

Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes 2012; 60(3): 234-43.

Nolting T, Lindecke A, Hartung H-P, et al. Cytokine levels in CSF and neuropsychological performance in HIV patients. Journal of Neuropsychology 2012; 18(3): 157-61.

Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Annals of Neurology 1995; 38(5): 755-62.

Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center: Annual Report 1997; 2: 67-72.

Wesselingh SL, Takahashi K, Glass JD, McArthur JC, Griffin JW, Griffin DE. Cellular localization of tumor necrosis factor factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry. Journal of Neuroimmunology 1997; 74(1-2): 1-8.

Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death and Differentiation. 2005;12(Suppl 1):878-92.

Williams KC, Corey S, Westmoreland SV, et al. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. Journal of Experimental Medicine 2001; 193(8): 905-15.

González-Scarno F, Martín-García J. The neuropathogenesis of AIDS. Nature Reviews Immunology 2005; 5(1): 69–81.

Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410(6831): 968-94.

Mörner A, Thomas JA, Björling E, Munson PJ, Lucas SB, McKnight A. Productive HIV-2 infection in the brain is restricted to macrophages/microglia. AIDS 2003; 17(10): 1451-5.

Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartementalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathogens. 2009;5(4):e1000395.

Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathogens 2011; 7(10): e1002286.
Petito CK. Human immunodeficiency virus type 1 compartmentalization in the central nervous system. Journal of Neurovirology 2004; 10 Suppl 1: 21-4.

Nottet HS, Persidsky Y, Sasseville VG, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. Journal of Immunology 1996; 156(3): 1284-95.

Bagasra O, Lavi E, Bobroski L, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996; 10(6): 573-85.

Mukhtar M, Pomerantz RJ. Development of an in vitro blood-brain barrier model to study molecular neuropathogenesis and neuroendocrine disorders induced by human immunodeficiency virus type 1 infection. Journal of Human Virology 2000; 3(6): 324-34.

Gujalvula C, Burns AR, Pushkarsky T, et al. HIV-1 penetrates coronary artery endothelial cells by transcytosis. Molecular Medicine 2001; 7(3): 169-76.

Liu NQ, Lossinsky AS, Pegg EC, et al. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. Journal of Virology. 2002;76(13):6689-700.

Argyris EG, Acheampong E, Nunnari G, Mukhtar M, Williams KJ, Pomerantz RJ. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. Journal of Virology; 2003; 77(22): 12140-51.

Willey SJ, Reeves JD, Hudson R, et al. Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells. Journal of Virology 2003; 77(11): 6138-52.

Fischer-Smith T, Rappaport J. Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Reviews in Molecular Medicine 2005; 7(27): 1-26.

Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Willey SJ. Cortical dendritic pathology in human immunodeficiency virus encephalitis. Laboratory Investigation 1992; 66(3): 285-91.

Willey SJ, Masliah E, Morey M, et al. Neocortical damage during HIV infection. Annals of Neurology 1991; 29(6): 651-7.

Gelbard HA, James HJ, Shaver LR, et al. Apoptotic neurons in brains from paediatric patients with HIV-1 encephalitis and progressive encephalopathy. Neurpathology and Applied Neurobiology 1997; 23(3): 208-17.

Petito CK, Roberts B. Evidence of apoptotic cell death in HIV-1 infected macrophages. Journal of Virology, Current HIV Research 2012; 10(5): 392-406.

Fan Y, Zou W, Green LA, Kim BO, He JJ. Activation of Erk-1 expression in astrocytes by HIV-1 Tat: new insights into astrocyte-mediated Tat neurotoxicity. Journal of Neuroimmunopharmacology. 2011; 6(1): 121-9.

O'Donnell LA, Agrawal A, Jordan-Scuitti KL, Dichter MA, Lynch DR, Kolson DL. Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. Journal of Neuroimmunopharmacology. 2006; 9(1): 981-90.

Anderson ER, Gendelman HE, Xiong H. Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. Journal of Neurosciences. 2004; 24(32): 7194-8.

Meisner F, Scheller C, Kneitz S, et al. Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 2008; 33(9): 2259-75.

Jiang ZG, Piggee C, Heyes MP, et al. Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. Journal of Neuroimmunology 2001; 117(1-2): 97-107.

Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Annals of Neurology 1991; 29(2): 202-9.

Heyes MP, Brew BJ, Saito K, et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. Journal of Neuroimmunology 1992; 40(1): 71-80.

Gulian D, Yu J, Li X, et al. Study of receptor-mediated neurotoxins released by HIV-1-infected mononuclear phagocytes found in human brain. Journal of Neuroscience 1996; 16(10): 3139-53.

Gelbard HA, Nottet HS, Swindells S, et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1 induced neurotoxin. Journal of Virology 1994; 68(7): 4628-35.

Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. Journal of Clinical Investigation 1993; 91(6): 2769-75.

Pulliam L, West D, Haigwood N, Swanson RA. HIV-1 envelope gp120 alters astrocytes in human brain cultures. AIDS Research and Human Retroviruses 1993; 9(5): 439-44.

Lipton SA. Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. Neuroreport. 1992; 3(10): 913-5.

Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. Journal of Infectious Diseases 2002; 186 Suppl 2: S193-8.

Ferrarese C, Aliprandi A, Tremolizzo L, et al. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 2001; 57(4): 671-5.

Espey MG, Ellis RJ, Heaton RK, Basile AS. Relevance of glutamate levels in the CSF of patients with HIV-1-associated dementia complex. Neurology 1999; 53(5): 1144-5.

Espey MG, Basile AS, Heaton RK, Ellis RJ. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology. 2002;58(9):1439; author reply –40.
[121] Martin A, Heyes MP, Salazar AM, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. Journal of Neuropsychiatry and Clinical Neurosciences 1992; 4(3): 270-9.

[122] Shibahara S, Müller RM, Taguchi H. Transcriptional control of rat heme oxygenase by heat shock. Journal of Biological Chemistry 1994; 269(27): 12889-92.

[123] Taketani S, Kohno H, Yoshinaga T, Tokunaga R. Induction of heme oxygenase in rat hepatoma cells by exposure to heavy metals and hyperthermia. Biochemistry International 1988; 17(4): 665-72.

[124] Ewing JF, Haber SN, Maines MD. Normal and heat-induced patterns of expression of heme oxygenase-1 (HSP32) in rat brain: hyperthermia causes rapid induction of mRNA and protein. Journal of Neurochemistry 1992; 58(3): 1140-9.

[125] Ewing JF, Maines MD. Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: heme oxygenase 2 is not a heat shock protein. Proceedings of the National Academy of Sciences of the United States of America 1991; 88(12): 5364-8.

[126] Dwyer BE, Nishimura RN, De Vellis J, Yoshida T. Heme oxygenase is a heat shock protein after renal ischemia. Journal of Physiology 1996; 270(4): L517-L25.

[127] Maines MD, Ewing JF. Stress response of the rat testis: in situ hybridization and immunohistochemical analysis of heme oxygenase-1 (HSP32) induction by hyperthermia. Biology of Reproduction 1996; 54(5): 1070-9.

[128] Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein in rat retinal tissue. Glia 1992; 5(4): 300-5.

[129] Eyssen-Hernandez R, Ladoux A, Frelin C. Differential regulation of cardiac heme oxygenase-1 and vascular endothelial growth factor mRNA expressions by hemin, heavy metals, heat shock and anoxia. FEBS Letters 1996; 382(3): 229-33.

[130] Nimura T, Weinstein PR, Massa SM, Panter S. Heme oxygenase-1 (HO-1) protein induction in rat brain following focal ischemia. Molecular Brain 1996; 37(1-2): 201-8.

[131] Visnes GA, Fogg S, Nick HS. Hypoxia-responsive proteins in rat pulmonary microvascular endothelial cells. American Journal of Physiology 1996; 270(4): L517-L25.

[132] Sunderman FW. Metal induction of heme oxygenase. Annals of the New York Academy of Sciences 1987; 514: 65-80.

[133] Opanashuk LA, Finkelstein JS. Relationship of lead-induced proteins to stress response proteins in astroglial cells. Journal of Neuroscience Research 1995; 42(5): 623-32.

[134] Stocker R. Induction of haem oxygenase as a defence against oxidative stress. Free Radical Research Communications 1990; 9(2): 101-12.

[135] Clerget M, Polla BS. Erythropagocytosis induces heat shock protein synthesis by human monocytes-macrophages. Proceedings of the National Academy of Sciences of the United States of America 1990; 87(3): 1081-5.

[136] Saunders EL, Maines MD, Meredith MJ, Freeman ML. Enhancement of heme oxygenase-1 synthesis by glutathione depletion in Chinese hamster ovary cells. Archives of Biochemistry and Biophysics 1991; 288(2): 368-73.

[137] Katoh T, Ohmori H, Murakami T, Karasaki Y, Higashi K, Sato H, Ishii T, Sugita Y, Tateishi N, Bannai S. Induction of a 23 kDa stress protein by oxidative and sulfhydryl-reactive agents in mouse peritoneal macrophages. Biochimica et Biophysica Acta 1993; 1148(1): 127-32.

[138] Yamanouchi M, Sato H, Bannai S. Induction of stress proteins in mouse peritoneal macrophages by oxidized low-density lipoprotein. Biochemical and Biophysical Research Communications 1993; 193(3): 1196-200.

[139] Hoshida S, Nishida M, Yamashita N, et al. Heme oxygenase-1 expression and its relation to oxidative stress during primary culture of cardiomyocytes. Journal of Molecular and Cellular Cardiology. 1996; 28(9): 1845-55.

[140] McDonagh AF. Is bilirubin good for you? Clinics in Perinatology 1990; 17(2): 359-69.

[141] Ryter SW, Choi AMK. Heme Oxygenase-1/Carbon Monoxide. American Journal of Respiratory Cell and Molecular Biology 2009; 41(3): 251-60.

[142] Smith MA, Kutty RK, Richey PL, et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. American Journal of Pathology 1994; 145(1): 42.

[143] Schipper HM, Cisssi S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Annals of Neurology 1995; 37(6): 758-68.

[144] Takeda A, Perry G, Abraham N, et al. Overexpression of Heme Oxygenase in Neuronal Cells, the Possible Interaction with Tau. Journal of Biological Chemistry 2000; 275(8): 5395-9.

[145] Schipper HM, Cisssi S, Stopa EG. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Experimental Neurology 1998; 150(1): 60-8.

[146] Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Research 1996; 737(1-2): 195-200.

[147] Mateo I, Infante J, Sanchez-Juan P, et al. Serum heme oxygenase-1 levels are increased in Parkinson's disease but not in Alzheimer's disease. Acta Neurologica Scandinavica 2010; 121(2): 136-8.

[148] Castellani R, Smith MA, Richey PL, Kalaria R, Gambetti P, Perry G. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Research 1995; 696(1-2): 268-71.

[149] Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathology 1999; 9(1): 147-63.

[150] Mehndite K, Sahlas DJ, Frankel D, et al. Proinflamatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. Journal of Neurochemistry 2001; 77(5): 1386-95.

[151] Pagone P, Patti F, Mangano K, et al. Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. Journal of Neuroimmunology 2013; 261(1-2): 82-6.

[152] Schipper HM. Heme oxygenase-1: role in brain aging and neurodegeneration. Experimental Gerontology 2000; 35(6-7): 821-30.

[153] Schipper HM. Heme oxygenase expression in human central nervous system disorders. Free Radical Biology and Medicine 2004; 37(12): 1995-2011.

[154] Schipper HM, Gupta A, Szarek WA. Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. Current Alzheimer Research 2009; 6(5): 424-30.

[155] Jazwa A, Cuadrado A. Targeting heme oxygenase-1 for neuroprotection: Cis- and trans-Induction in neurodegenerative diseases. Current Drug Targets 2010; 11(12): 1517-31.

[156] Cross SA, Cook DR, Chi AWS, et al. Dimethyl Fumarate, an Immune Modulator and Inducer of the Antioxidant Response, Suppresses HIV Replication and Macrophage-Mediated Neurotoxicity: A Novel Candidate for HIV Neuroprotection. Journal of Immunology 2011; 187(10): 5015-25.

[157] Bornman L, Baladi S, Richard MJ, Tyrrell RM, Polla BS. Differential regulation and expression of stress proteins and ferritin in human monocytes. Journal of Cellular Physiology 1999; 181(4): 391-401.

[158] Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409(6817): 198-201.

[159] Schaer DJ, Schaer CA, Buehler PW, et al. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobin in the absence of haptoglobin. Blood 2006; 107(1): 373-80.

[160] Schipper CA, Vallianet F, Imhof A, Schoedon G, Schaer DJ. CD163-expressing monocytes constitute an endotoxin-sensitive Hb clearance compartment within the vascular system. Journal of Leukocyte Biology 2007; 82(1): 106-10.

[161] Philippidis P, Mason JC, Evans BJ, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circulation Research 2004; 94(1): 119-26.

[162] Delaby C, Pilard N, Hetet G, et al. A physiological model to study iron recycling in macrophages. Experimental Cell Research 2005; 310(1): 43-53.
[165] Schaefer CA, Schoedon G, Imhof A, Kurrier MO, Schaefer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circulation Research 2006; 99(9): 943-50.

[166] Kovtunovych G, Eckhaus MA, Ghosh MC, Ollivierre-Wilson H, Rouault TA. Dysfunction of the heme recycling system in heme oxygenase-1-deficient mice: effects on macrophage viability and tissue iron distribution. Blood 2010; 116(26): 6054-62.

[167] Turcanu V, Dhouib M, Poin dron P. Nitric oxide synthase inhibition by haem oxygenase decreases macrophage nitric-oxide-dependent cytotoxicity: a negative feedback mechanism for the regulation of nitric oxide production. Research in Immunology 1998; 149(7-8): 741-4.

[168] Wagener FADTG, van Beurden HE, von den Hoff JW, Adema GJ, Gleissner CA, Shaked I, Erbel C, Böckler D, Katus HA, Ley K. Hvidberg V, Maniecki MB, Jacobsen C, Højrup P, Møller HJ, Srisook K, Cha YN. Cytotoxic and cytoprotective actions of HO-1 in macrophages and neutrophils via the pentapeptide antismooth muscle factor. Journal of Immunology 2005; 177(2): 615-23.

[169] Lang D, Reuter S, Bužescu T, August C, Heidenreich S. Heme-induced heme oxygenase-1 (HO-1) in human monocytes inhibits apoptosis despite caspase-3 up-regulation. International Immunology 2005; 17(2): 155-69.

[170] Hvidberg V, Maniecki MB, Jacobsen C, Höstrup P, Möller HJ, Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood 2005; 106(7): 2572-9.

[171] Gleisner CA, Shaked I, Erbel C, Böckler D, Katus HA, Ley K. Hvidberg V, Maniecki MB, Jacobsen C, Højrup P, Møller HJ, Srisook K, Cha YN. Super-induction of HO-1 in macrophages and neutrophils via the pentapeptide antismooth muscle factor. Journal of Immunology 2005; 177(2): 615-23.

[172] Pham N-K, Mouriz J, Kima PE. Leishmania pifanoi amastigotes avoid macrophage production of superoxide by inhibiting heme degradation. Infection and Immunity 2005; 73(12): 8322-33.

[173] Orozco LD, Kapturczak MH, Barajas B, et al. Heme oxygenase-1 expression in macrophages plays a beneficial role in atherosclerosis. Circulation Research 2007; 100(12): 1703-11.

[174] Taketani S, Sato H, Yoshinaga T, Tokunaga R, Ishii T, Bannai S. Heme oxygenase-1 affords protection against noncerebral forms of severe malaria. Nature Medicine 2007; 13(6): 703-10.

[175] Paine A, Eiz-Vesper B, Blaszczyk R. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochemical Pharmacology 2010; 80(12): 1895-903.

[176] Srisook K, Cha YN. Cytotoxic and cytoprotective actions of O2- and NO (ONOO-) are determined both by cellular GSH level and HO activity in macrophages. Methods in Enzymology 2005; 396: 414-24.

[177] Ryter S, Choi A. Heme oxygenase-1: molecular mechanisms of gene expression in oxygen-related stress. Antioxidants and Redox Signaling 2002; 4(4): 625-32.

[178] Camhi SL, Alam J, Otterbein L, Sylvester SL, Choi AM. Induction of HO-1 gene expression by lipopolysaccharide is mediated by AP-1 activation. American Journal of Respiratory Cell and Molecular Biology 1996; 38(2): 251-9.

[179] Schachtele SJ, Hu S, Lokensgard JR. Modulation of experimental herpes encephalitis-associated neurotoxicity through sulforaphane treatment. PLoS One 2012; 7(4): e36216.

[180] Yachie A, Toma T, Mizuno K, et al. Heme oxygenase-1 production by peripheral blood monocytes during acute inflammatory illnesses of children. Experimental Biology and Medicine 2003; 228(5): 550-6.

[181] Regev D, Surolia S, Karaki S, et al. Heme oxygenase-1 promotes granulosa development and protects against dissemination of ovarian cancer. Lab Investigation 2012; 92(11): 1541-52.

[182] Zacharia VM, Shiloh MU. Effect of carbon monoxide on Mycobacterium tuberculosis pathogenesis. Medical Gas Research 2012; 2(1): 30.

[183] Fuji S, Akaite T, Maeda H. Role of nitric oxide in pathogenesis of herpes simplex virus encephalitis in rats. Virology 1999; 256(2): 203-12.

[184] Schachttele SJ, Hu S, Lokengard JR. Modulation of experimental herpes encephalitis-associated neurotoxicity through sulforaphane treatment. PLoS One 2012; 7(4): e36216.

[185] Yachie A, Toma T, Mizuno K, et al. Heme oxygenase-1 production by peripheral blood monocytes during acute inflammatory illnesses of children. Experimental Biology and Medicine 2003; 228(5): 550-6.
Orihara Y, Tsuda R, Ikematsu K, Nakasono I, Ogata M. Immunohistochemical study on the induction of heme oxygenase-1 by traumatic brain injury. Legal Medicine 2003; 5 (Suppl 1):S278-9.

Sutherland BA, Rahman RMA, Clarkson AN, Shaw OM, Nair SM, Appleton I. Cerebral heme oxygenase 1 and 2 spatial distribution is modulated following injury from hypoxia-ischemia and middle cerebral artery occlusion in rats. Neuroscience Research 2009; 65(4): 326-34.

Fukuda K, Richmon JD, Sato M, Sharp FR, Panter SS, Noble LJ. Induction of heme oxygenase-1 (HO-1) in glia after traumatic brain injury. Brain Research 1996; 736(1-2): 68-75.

Hirata K, He JW, Kuraoka A, et al. Heme oxygenase1 (HSP-32) is induced in myelin-phagocytosing Schwann cells of injured sciatic nerves in the rat. European Journal of Neuroscience 2000; 12(11): 4147-52.

Jelinski SE, Yager JY, Juurlink BH. Preferential injury of oligodendroblasts by a short hypoxic-ischemic insult. Brain Research 1999; 815(1): 150-3.

Fukuda K, Scott Panter S, Sharp FR, Noble LJ. Induction of heme oxygenase-1 (HO-1) after traumatic brain injury in the rat. Neuroscience Letters 1995; 199(2): 127-30.

Wang J, Doré S. Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain 2007; 130(Pr 6): 1643-52.

Zhang Z, Zhang Z-Y, Wu Y, Schluesener HJ. Lesional accumulation of CD163+ macrophages/microglia in rat traumatic brain injury. Brain Research 2012; 1461: 102-10.

Liu Y, Zhang Z, Luo B, Schluesener HJ, Zhang Z. Lesional accumulation of heme oxygenase-1+ microglia/macrophages in rat traumatic brain injury. Neuroreport 2013; 24(6): 281-6.

Richmon JD, Fukuda K, Maida N, et al. Induction of heme oxygenase-1 after hyperosmotic opening of the blood-brain barrier. Brain Research 1998; 780(1): 108-18.

Beschorner R, Adjodah D, Schwab JM, et al. Long-term expression of heme oxygenase-1 (HO-1, HSP-32) following focal cerebral infarctions and traumatic brain injury in humans. Acta Neurochirurgica 2000; 100(4): 377-84.

Jofre-Monseny L, Loboda A, Wagner AE, et al. Effects of apoE genotype on macrophage inflammation and heme oxygenase-1 expression. Biochemical and Biophysical Research Communications 2007; 357(1): 319-24.

Nijboer WN, Schuurs TA, van der Hoeven JAB, et al. Effect of brain death on gene expression and tissue activation in human donor kidneys. Transplantation 2004; 78(7): 978-86.

Wang W, Wang H-D, Zhu L, et al. Traumatic brain injury induces the activation of the Nrf2-ARE pathway in the lung in rats. Brain Injury 2008; 22(10): 802-10.

Acarin L, Paris J, González B, Castellano B. Glial expression of asialoorosomucoid by nicotine attenuates inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. American Journal of Pathology 2011; 179(3): 1360-72.

Tzima S, Victoratos P, Kranidioti K, Alexiou M, Kollias G. Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. Journal of Experimental Medicine. 2009; 206(5): 1167-79.

Yamada K, Tanaka N, Nakashiki K, et al. Modulation of the secondary injury process after spinal cord injury in Bach1-deficient mice by heme oxygenase-1. Journal of Neurosurgery Spine 2010; 166(3): 1151-68.

Wang J, Doré S. Heme oxygenase 2 deficiency increases brain swelling and inflammation after intracerebral hemorrhage. Neuroscience 2008; 155(4): 1133-41.

Grochot-Przeczyk A, Dulak J, Jozkowicz A. Haem oxygenase-1: non-canonical roles in physiology and pathology. Clinical Science 2012; 122(3): 93-103.

Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. Journal of Biological Chemistry 2000; 275(21): 16023-9.

Vijayan V, Baumgart-Vogt E, Naidu S, Qian G, Immenschuh S. Bruton's tyrosine kinase is required for TRL-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages. Journal of Immunology 2011; 187(2): 817-27.

Kim KH, Lyu JH, Koo ST, et al. MyD88 is a mediator for the activation of Nrf2. Biochemical and Biophysical Research Communications 2011; 404(1): 46-51.

Mandal P, Roychowdhury S, Sengupta PH, Adiponectin and heme oxygenase-1 suppress TLR4/MyD88-independent signaling in rat Kupffer cells and in mice after chronic ethanol exposure. Journal of Immunology 2012; 189(1): 4028-37.

Yin H, Li X, Yuan B, et al. Heme oxygenase-1 ameliorates LPS-induced acute lung injury correlated with downregulation of interleukin-6. International Immunopharmacology 2011; 11(12): 2112-7.

Wang XM, Kim HP, Nakahira K, Ryter SW, Choi AMK. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the expression of TLR4 with caveolin-1. Journal of Immunology 2009; 182(6): 3809-18.

Ke B, Shen X-D, Ji H, et al. HO-1-STAT3 axis in mouse liver ischemia/reperfusion injury: regulation of TLR4 innate responses through PI3K/PI3K signaling. Journal of Hepatology 2012; 56(2): 359-66.

Tsui K, Jiang JH, Kim JW, et al. Induction of alpha2 nicotinic acetylcholine receptor by nicotine attenuates inflammatory response in macrophages and improves survival in experimental model of sepsis through heme oxygenase-1 induction. Antioxidants and Redox Signaling 2011; 14(11): 2057-70.

Sun J, Kim SJ, Park MK, et al. Selective activation of adrenergic beta1 receptor induces heme oxygenase-1 production in RAW264.7 cells. FEBS Letters 2005; 579(25): 5494-500.

Rushworth SA, Chen X-L, Mackman N, Ogborne RM, O'Connell MA. Lipopolysaccharide-induced heme oxygenase-1 expression in human monocytic cells is mediated via Nrf2 and protein kinase C. Journal of Immunology 2005; 175(7): 4408-15.

Park SY, Kim YH, Kim E-K, Ryu EY, Lee SJ. Heme oxygenase-1 signals are involved in preferential inhibition of pro-inflammatory cytokine release by surfactin in cells activated with Porphyromonas gingivalis lipopolysaccharide. Chemico-Biological Interactions 2010; 188(3): 437-45.

Ogawa M, Stahl-Biskupek B, Stahl D. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB signaling in pro-inflammatory macrophage activation. J Neuroinflammation 2012; 9: 126.

Lee SE, Jeong SI, Yang H, et al. Extract of Salvia miltiorrhiza (Danshen) induces Nrf2-mediated heme oxygenase-1 expression as a cytoprotective action in RAW 264.7 macrophages. Journal of Ethnopharmacology 2012; 139(2): 541-48.

Gao X, Kang Y, Zhang D, et al. The flavonoid kaempferol protects the lung against endotoxin-induced inflammatory injury through the modulation of the TLR4/NF-kappaB pathway in vivo. Journal of Immunology 2009; 183(3): 1170-6.

Lee TS, Chau L-Y. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nature Medicine 2002; 8(3): 240-6.

Wu WT, Chi K-H, Ho F-M, Tsao W-C, Lin W-W. Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB activation. Biochemical Journal 2004; 379(Pt 3): 587.

Chen JS, Huang PH, Wang CH, Lin FY, Tsai HY. Nrf2 mediated heme oxygenase-1 expression, an antioxidant-independent mechanism, contributes to anti-atherogenesis and vascular protective effects Ginkgo biloba. Atherosclerosis 2011; 214(2): 301-9.

Jiang JH, Kim YM, Tsui K, et al. Ethyl pyruvate induces heme oxygenase-1 through p38 mitogen-activated protein kinase activation by depletion of glutathione in RAW 264.7 cells and improves survival in septic animals. Antioxidants and Redox Signaling 2012; 17(6): 878-99.

Kurachi Y, Hisatsune A, Isohama Y, Mishima S, Katsuki S. Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase-1 and brain-derived neurotrophic factor. British Journal of Pharmacology 2012; 166(3): 1151-68.
Piantadosi CA, Withers CM, Bartz RR, Drechsler Y, Dolganiuc A, Norkina O, Pittock ST, Norby SM, Grande JP, Inoue S, Suzuki M, Nagashima Y, Kamimoto M, Mizuno S, Nakamura T. Reciprocal regulation of IL-
Camhi SL, Alam J, Wiegand GW, Chin BY, Choi AM. Lee PJ, Alam J, Sylvester SL, Inamdar N, Otterbein L, Choi AM. Bauer I, Rensing H, Florax A, Wijayanti N, Kietzmann T, Immenschuh S. Heme oxygenase-1
Sassone-Corsi P. Coupling gene expression to cAMP signalling: Camhi SL, Alam J, Wiegand GW, Chin BY, Choi AM. Lee PJ, Alam J, Sylvester SL, Inamdar N, Otterbein L, Choi AM. Bauer I, Rensing H, Florax A, Wijayanti N, Kietzmann T, Immenschuh S. Heme oxygenase-1
Walterez R, Weller M. Signaling from cAMP/PKA to MAPK and synaptic plasticity. Molecular Neurobiology 2003; 27(1): 99-106. Lavrovsky Y, Schwartzman ML, Abraham NG. Novel regulatory sites of the human heme oxygenase-1 promoter region. Biochemical and Biophysical Research Communications 1995; 196(1): 336-41. Wijayanthy N, Kietzmann T, Immenschuh S. Heme oxygenase-1 gene activation by the NAD(P)H oxidase inhibitor 4(2-aminooethyl) benzenesulfenyl fluoride via a protein kinase B, p38-dependent signaling pathway in monocytes. Journal of Biological Chemistry 2005; 280(23): 21820-9. Bauer I, Rensing H, Florax A, et al. Expression pattern and regulation of heme oxygenase-1/heat shock protein 32 in human liver cells. Shock 2003; 20(2): 116-22. Roach JP, Moore EE, Partrick DA, et al. Heme oxygenase-1 induction in macrophages by a hemoglobin-based oxygen carrier reduces endotoxin-stimulated cytokine secretion. Shock 2009; 31(3): 251-7. Pittock ST, Norby SM, Grande JP, et al. MCP-1 is up-regulated in unstimmed and stimulated HO-1 knockout mice: Pathophysiologic correlates. Kidney International 2005; 68(2): 611-22. Inoue S, Suzuki M, Nagashima Y, et al. Transfer of heme oxygenase 1 cDNA by a replication-deficient adenovirus enhances interleukin 10 production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice. Human Gene Therapy 2001; 12(8): 967-79. Kamimoto M, Mizuno S, Nakamura T. Reciprocal regulation of IL-6 and IL-10 balance by HGF via recruitment of heme oxygenase-1 in macrophages for attenuation of liver injury in a mouse model of endotoxemia. International Journal of Molecular Medicine 2009; 24(2): 161-70. Sierra-Filardi E, Vega MA, Sánchez-Mateos P, Corbi AL, Puig-Kröger A. Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiology 2010; 215(9-10): 788-95. Piantadosi CA, Withers CM, Bartz RR, et al. Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression. Journal of Biological Chemistry 2011; 286(18): 16274-85. Drechsler Y, Dolganiuc A, Norkina O, et al. Heme oxygenase-1 mediates the anti-inflammatory effects of acute alcohol on IL-10 induction involving p38 MAPK activation in monocytes. Journal of Immunology 2006; 177(4): 2592-600. Chauveau C, Rémy S, Royer PJ, et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005; 106(5): 1694-702. Tullius SG, Nieminen-Kelhää M, Buelow R, et al. Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt-protoporphyrin for the induction of heme oxygenase-1. Transplantation 2002; 74(5): 591-8. Shen X-D, Ke B, Uchida Y, et al. Novel regulatory mechanisms genetically modified to express heme oxygenase 1 protect rat liver transplants from ischemia/reperfusion injury. Liver Transplantation 2011; 17(2): 201-10. Kämpfer H, Kolb N, Manderscheid M, Wetzler C. Macrophage-derived heme-oxygenase-1: expression, regulation, and possible role in skin repair. Molecular Medicine 2001; 7(7): 488-98. Morse D, Pischke SE, Zhou Z, et al. Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1. Journal of Biological Chemistry 2003; 278(39): 36993-8. Zhong Y, Liu T, Lai W, Tan Y, Tian D, Guo Z. Heme oxygenase-1-mediated reactive oxygen species reduction is involved in the inhibitory effect of curcumin on lipopolysaccharide-induced monocyte chemotactant protein-1 production in RAW264.7 macrophages. Molecular Medicine Reports 2013; 7(1): 242-6. Sacerdotti D, Colombrita C, Ghattas MH, et al. Heme oxygenase-1 transduction in endothelial cells causes downregulation of monocyte chemotactant protein-1 and of genes involved in inflammation and growth. Cellular and Molecular Biology 2005; 51(4): 363-70. Ricchetti GA, Williams LM, Foxwell BMJ. Heme oxygenase 1 expression induced by IL-10 requires STAT-3 and phosphoinositol-3 kinase and is inhibited by lipopolysaccharide. Journal of Leukocyte Biology 2004; 76(3): 719-26. Kirino Y, Takeno M, Murakami S, et al. Tumor necrosis factor α acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis and Rheumatism 2007; 56(2): 464-75. Ke B, Shen X-D, Tsuchihashi S-I, et al. Viral interleukin-10 gene transfer prevents liver ischemia-reperfusion injury. Toll-like receptor-4 and heme oxygenase-1 signaling in innate and adaptive immunity. Human Gene Therapy 2007; 18(4): 355-66. Koch N, Jung M, Sabat R, et al. IL-10 protects monocytes and macrophages from complement-mediated lysis. Journal of Leukocyte Biology 2009; 86(1): 155-66. Petit-Bertron A-F, Fitting C, Cavallion J-M, Adb-Conquy M. Adherence influences monocyte responsiveness to interleukin-10. Journal of Leukocyte Biology 2003; 73(1): 145-54. Mizuno T, Doi Y, Mizoguchi H, et al. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. American Journal of Pathology 2011; 179(4): 2016-27. Kanakiriya SKR, Croatt AJ, Haggard JJ, et al. Heme: a novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms. American Journal of Physiology Renal Physiology 2003; 284(3): F546-54. Cao J, Sodhi K, Inoue K, et al. Lentinival-human heme oxygenase targeting endothelium improved vascular function in angiotensin II animal model of hypertension. Human Gene Therapy 2011; 22(3): 271-82. Park JH, Oh S-M, Lim SS, et al. Induction of heme oxygenase-1 mediates the anti-inflammatory effects of the ethanol extract of Rubus coreanus in murine macrophages. Biochemical and Biophysical Research Communications 2006; 351(1): 146-52. Kim B-C, Choi J-W, Hong H-Y, et al. Heme oxygenase-1 mediates the anti-inflammatory effect of mushroom Phellinus linteus in LPS-stimulated RAW264.7 macrophages. Journal of Ethnopharmacology 2006; 106(3): 364-71. Oh HM, Kang YJ, Lee YS, et al. Protein kinase G-dependent heme oxygenase-1 induction by Agastache rugosa leaf extract protects RAW264.7 cells from hydrogen peroxide-induced injury. Journal of Ethnopharmacology 2006; 103(2): 229-35. Shyu L-F, Huang C-C, Iiu Y-Y, Cheng Y-W, Yang S-D. A sesquiterpenol extract potent suppresses inflammation in macrophages and mice and prevents chronic liver damage in mice through JNK-dependent HO-1 expression. Phytochemistry 2011; 72(4-5): 391-9. Jun MS, Kim HS, Kim YM, et al. Ethanol extract of Prunella vulgaris var. Illiciana inhibits HMGB1 release by induction of heme
